Latest Breaking News On - Prnewswire moleculin biotech inc - Page 3 : comparemela.com

Moleculin to Participate in the Virtual Investor Lunch Break: The Moleculin Opportunity

/PRNewswire/ Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug.

United statesJenene thomasWalter klempMoleculin biotech incPrnewswire moleculin biotech incChief executive officerVirtual investor lunch breakMoleculin opportunityMoleculin biotechTranscription modulator

Moleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial

– Annamycin in combination with Cytarabine achieves CRc rate of 60% in 2nd line AML subjects – AnnAraC has potential to fill significant unmet need and expected to increase 2nd.

United statesWalter klempCytarabine annaraJenene thomasMoleculin biotech incSecurities exchangeExchange commissionPrnewswire moleculin biotech incAcute myeloid leukemiaFiscal yearChief executive officerAnnamycin responsesMoleculin biotech conferenceMoleculin biotechTranscription modulatorSecurities act

Moleculin to Present at the 36th Annual ROTH Conference

Moleculin to Present at the 36th Annual ROTH Conference
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesJenene thomasJonathan fosterMoleculin biotech incPrnewswire moleculin biotech incChief financial officerMoleculin biotechTranscription modulator

Moleculin Announces Pricing of $4 5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market

Moleculin Announces Pricing of $4 5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesJenene thomasSecurities exchangeSyndicate departmentMaxim groupPrnewswire moleculin biotech incExchange commissionMoleculin biotech incSecurities actMoleculin biotechTranscription modulatorSecurities exchange actPrivate securities litigation reform act

Moleculin to Participate in the Virtual Investor Ask the CEO Conference

Live video webcast with Walter Klemp, CEO and Jonathan Foster, Executive VP and CFO of Moleculin on Tuesday, October 25th at 12:00 PM ET HOUSTON, Oct. 11, 2023 /PRNewswire/ Moleculin Biotech,.

United statesJonathan fosterWalter klempJenene thomasPrnewswire moleculin biotech incMoleculin biotech incChief executive officerChief financial officerVirtual investor askMoleculin biotechTranscription modulator